Whole-genome sequencing to identify genetic mutation; epidemiological studies to help assess the distribution and mathematical modelling to forecast spread
Deal for 100 million doses with additional 100 million through 2023
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
It is part of the company’s pain/analgesics portfolio of OTC products
Startup receives US $ 5 million in first round of funding
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines
WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO
Price band in the range of Rs 933 to Rs 954
The company posted net profit of Rs.89.20 crores for the period ended June 30, 2020.
Subscribe To Our Newsletter & Stay Updated
